Photo from Krishan Jethwa/X
Aug 25, 2024, 16:00
Krishan Jethwa: Interpreting the benefit of RAPIDO Trial in high-risk rectal cancer
Krishan Jethwa, Assistant Professor of Radiation Oncology at Mayo Clinic, shared on X:
“A consideration in interpreting the benefit for high-risk rectal cancer in RAPIDO Trial was that only ~ 40% got post-op chemo in the CRT arm leading some to hypothesize that post-op chemo would have decreased DM, LRR, and DrTF, thus skewing the primary result towards the null.”
Source: Krishan Jethwa/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 29, 2025, 06:37
Mar 29, 2025, 06:23
Mar 29, 2025, 06:05
Mar 29, 2025, 04:55
Mar 29, 2025, 04:16
Mar 28, 2025, 20:11
Mar 28, 2025, 19:58